Ask AI
ProCE Banner Activity

Charting the Course: Antivirals for Refractory CMV Infections

Video

Stream this webcast to learn to appropriately modify antiviral therapy in solid organ transplant recipients with treatment-refractory cytomegalovirus (CMV) infections.

Released: August 14, 2025

Share

Provided by

Provided by Clinical Care Options (CCO) in partnership with ProCE, LLC

ProCE Banner

Supporters

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc.

Partners

ProCE, LLC

ProCE Banner

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Employ best practices for timely identification of refractory CMV infections following solid organ transplantation

  • Appropriately modify antiviral therapy in solid organ transplant recipients with treatment refractory CMV infections

  • Design antiviral regimens for refractory CMV infections to minimize antiviral toxicities and maximize efficacy

Disclosure

Primary Author

Atul Humar, MD, FRCP (C): consultant/advisor/speaker: Eurofins, Merck, Takeda; researcher: Qiagen.

Camille Kotton, MD, FIDSA, FAST: consultant/advisor/speaker: Abbott, Merck, Qiagen, Roche, Takeda; researcher: Kamada, Takeda.